跳至主要内容
临床试验/NL-OMON50071
NL-OMON50071已完成不适用

Cellular & Serological Immune Response Monitoring in SARS-CoV2-infected individuals, without need of hospitalization - SARS-RESPONSE

eids Universitair Medisch Centrum0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational invasive

入排标准

年龄范围
18 至 99(—)

入选标准

  • Subject (male or female) tested positive for SARS-CoV2 by PCR (nasal swab,
  • throat swab and/or sputum);
  • Subject is an adult of 18-65 years old;
  • Subject is able to understand the PIF document, written in Dutch;
  • Subject is able to communicate well with the investigator in the Dutch
  • Subject signed informed consent prior to any study-mandated procedure;
  • Subject is living in Leiden or direct environment (e.g. within 10 km from
  • LUMC), allowing for traveling by car, bike or by walking to LUMC (no public
  • transportation).

排除标准

  • Subject tested negative upon SARS-CoV2 PCR re-analysis of nasal swab at
  • Subject previously fainted before, during or after a medical procedure with
  • Subject received plasma or other blood products during the previous 3 months;
  • Subject received a vaccination during the previous 3 months;
  • Subject is obese with BMI >=30, based on provide weight and length information;
  • Subject has a pre-existing coagulopathy;
  • Subject uses medication for a coagulopathy;
  • Subject uses medication that suppresses the immune system;
  • Subject has an auto-immune disease or another immune disease;
  • Subject has another infection in addition to the SARS-CoV2 infection;
  • Subject participated in a clinical trial within 6 months prior to this study;
  • For women: subject is pregnant or is providing breast-feeding.

研究者

相似试验